Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
12-21-2021

Tricuspid valve intervention at the time of pulmonary valve
replacement in adults with congenital heart disease: A systematic
review and meta-analysis
Jef Van den Eynde
Connor P Callahan
Mauro Lo Rito
Nabil Hussein
Horacio Carvajal

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Authors
Jef Van den Eynde, Connor P Callahan, Mauro Lo Rito, Nabil Hussein, Horacio Carvajal, Alvise Guariento,
Arjang Ruhparwar, Alexander Weymann, Werner Budts, Marc Gewillig, Michel Pompeu Sá, and Shelby
Kutty

Journal of the American Heart Association
SYSTEMATIC REVIEW AND META-ANALYSIS

Tricuspid Valve Intervention at the Time
of Pulmonary Valve Replacement in
Adults With Congenital Heart Disease: A
Systematic Review and Meta-Analysis
Jef Van den Eynde , BSc; Connor P. Callahan, MD; Mauro Lo Rito , MD; Nabil Hussein , MBChB (Hons);
Horacio Carvajal , MD; Alvise Guariento , MD; Arjang Ruhparwar, MD, PhD; Alexander Weymann, MD, PhD;
Werner Budts , MD, PhD; Marc Gewillig , MD, PhD; Michel Pompeu Sá , MD, PhD; Shelby Kutty , MD, PhD
BACKGROUND: Tricuspid regurgitation (TR) is a common finding in adults with congenital heart disease referred for pulmonary
valve replacement (PVR). However, indications for combined valve surgery remain controversial. This study aimed to evaluate
early results of concomitant tricuspid valve intervention (TVI) at the time of PVR.
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METHODS AND RESULTS: Observational studies comparing TVI+PVR and isolated PVR were identified by a systematic search
of published research. Random-effects meta-analysis was performed, comparing outcomes between the 2 groups. Six studies involving 749 patients (TVI+PVR, 278 patients; PVR, 471 patients) met the eligibility criteria. In the pooled analysis, both
TVI+PVR and PVR reduced TR grade, pulmonary regurgitation grade, right ventricular end-diastolic volume, and right ventricular end-systolic volumes. TVI+PVR, but not PVR, was associated with a decrease in tricuspid valve annulus size (mean
difference, −6.43 mm, 95% CI, −10.59 to −2.27; P=0.010). Furthermore, TVI+PVR was associated with a larger reduction in TR
grade compared with PVR (mean difference, −0.40; 95% CI, −0.75 to −0.05; P=0.031). No evidence could be established for
an effect of either treatment on right ventricular ejection fraction or echocardiographic assessment of right ventricular dilatation and dysfunction. There was no evidence for a difference in hospital mortality or reoperation for TR.
CONCLUSIONS: While both strategies are effective in reducing TR and right ventricular volumes, routine TVI+PVR can reduce TR
grade to a larger extent than isolated PVR. Further studies are needed to identify the subgroups of patients who might benefit
most from combined valve surgery.
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T

ricuspid regurgitation (TR) is a common finding
in adults with congenital heart disease (ACHD)
referred for pulmonary valve replacement (PVR),
including those with tetralogy of Fallot (TOF), pulmonary stenosis, and pulmonary atresia.1 Notably,
as many as three-quarters of these patients have
at least mild TR, and one-third present with at least
moderate TR. Despite clearly demonstrated benefits
of PVR on right ventricular (RV) volumes and function

and the observation that isolated PVR also reduces
TR, indications for combined valve surgery remain
controversial.2,3 Current guidelines do not suggest
when concomitant tricuspid valve intervention (TVI)
should be recommended.4,5 Nonetheless, severe TR
is strongly associated with an increased risk of adverse outcomes in ACHD.6 Therefore, we aimed to
evaluate early results of concomitant TVI at the time
of PVR.
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CLINICAL PERSPECTIVE
What Is New?

• In this systematic review and meta-analysis of
749 adults with congenital heart disease, we
demonstrated that concomitant tricuspid valve
intervention (TVI) at the time of pulmonary valve
replacement (PVR) helped reduce tricuspid regurgitation (TR) grade to a larger extent than
isolated PVR, while both strategies were otherwise equally effective.

What Are the Clinical Implications?

• Patients with severe preoperative TR would
probably derive the greatest benefit from concomitant TVI in terms of improvement in NYHA
class and TR grade; however, concomitant TVI
does not seem to be effective in reducing the
risk of adverse events such as death, arrhythmias, and heart failure.
• Current data therefore do not support the universal application of this approach for severe
TR.
• Further well-designed studies focusing on specific underlying mechanisms of TR and evaluating the effect on adverse events on long-term
follow-up may elucidate which patients stand to
benefit the most from this approach.
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Nonstandard Abbreviations and Acronyms
ACHD
MD
NYHA
PR
PVR
RVEDV
RVESV
TOF
TR
TV
TVI

adults with congenital heart disease
mean difference
New York Heart Association
pulmonary regurgitation
pulmonary valve replacement
right ventricular end-diastolic volume
right ventricular end-systolic volume
tetralogy of Fallot
tricuspid regurgitation
tricuspid valve
tricuspid valve intervention

METHODS
Eligibility Criteria, Databases, and Search
Strategy
The data that support the findings of this study are
available from the corresponding author upon reasonable request. We followed 2 internationally recognized
protocols: Preferred Reporting Items for Systematic
Reviews Meta-analyses7 and Meta-
analysis of

TVI at PVR: Meta-Analysis

Observational Studies in Epidemiology.8 Using the
Population, Interventions, Comparison, Outcome, and
Study Design strategy, studies were included if the following criteria were fulfilled:
1. The population comprised ACHD (including TOF,
pulmonary stenosis, and pulmonary atresia) who
developed at least moderate pulmonary valve
insufficiency;
2. The intervention group included patients who underwent combined TVI and PVR;
3. The control group included patients who underwent
isolated PVR;
4. Outcomes of the studies included any of the following:
tricuspid regurgitation (TR) grade, pulmonary regurgitation (PR) grade, tricuspid valve (TV) annulus size, RV
dilatation, RV dysfunction, RV end-diastolic volume
(RVEDV), RV end-systolic volume (RVESV), RV ejection fraction (RVEF), RV end-diastolic area, RV end-
systolic area, New York Heart Association (NYHA)
class, reoperation for TR, or 30-day mortality; and
5. Studies were prospective or retrospective observational studies or randomized controlled trials.
Databases were searched for articles meeting our inclusion criteria and published by December 29, 2020:
PubMed/MEDLINE, Embase, Scopus, and reference
lists of relevant articles. The detailed search terms that
were used for this search are given in Data S1. The following steps were taken: (1) identification of titles of records
through database searching, (2) removal of duplicates,
(3) screening and selection of abstracts, (4) assessment
for eligibility through full-text articles, and (5) final inclusion in study. Studies were selected by 2 independent
reviewers (C.C. and M.L.R.). When concordance was
absent, a third reviewer (J.V.D.E.) made the decision to
include or exclude the study.

End Points, Risk of Bias, and Statistical
Analysis
The primary end point of the study was TR grade. The
secondary end points were PR grade, TV annulus
size (mm), RV dilatation, RV dysfunction, RVEDV (mL),
RVESV (mL), RVEF (%), RV end-diastolic area (cm²),
RV end-systolic area (cm²), NYHA class, reoperation
for TR, or 30-day mortality. The grades of TR, PR, RV
dilatation, and RV dysfunction were quantitatively assessed on echocardiography and scored on a scale
from 0 to 3 (0, none; 1, mild; 2, moderate; 3, severe).
Postoperative measurements were defined as the first
observation within 12 months after surgery. For studies
reporting interquartile ranges, the mean was estimated
according to a validated formula.9 Two independent
reviewers (N.H. and A.G.) extracted the data. When
concordance was absent, a third reviewer (J.V.D.E.)
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checked the data and made the final decision. From
each study, we extracted patient characteristics, study
design, and outcomes.
The Risk of Bias in Nonrandomized Studies of
Interventions tool was systematically used to assess
the included studies for risk of bias.10 The articles and
their characteristics were classified into A (low risk of
bias), B (moderate risk of bias), C (serious risk of bias),
D (critical risk of bias), or E (no information/unclear).
Using the RoB 2 tool,11 the included randomized controlled trials were assessed for biases. Two independent reviewers (C.C. and M.L.R.) assessed the risk of
bias. When concordance was absent, a third reviewer
(J.V.D.E.) checked the data and made the final decision.
Mean differences (MD) with 95% CI and P values
were calculated for continuous variables. For binary
variables, odds ratios (ORs) with 95% CI and P values were considered. Forest plots were created to
represent the clinical outcomes. The chi-square test
and I2 test were performed for assessment of statistical heterogeneity.12 The MD and OR were combined
across the studies using a random-
effects method
(DerSimonian and Laird inverse variance).13 The choice
for random-effects models was made on the basis of
the assumption that the effect sizes in the individual
studies represented samples from a mixing distribution. In addition, the results were reanalyzed using
fixed-effects models to explore whether this yielded
differences regarding the summary inferences. The
risk of publication bias could not be assessed because
none of the comparisons included >10 studies.14,15 All
analyses were completed with R Statistical Software
(version 4.0.2, R Foundation for Statistical Computing,
Vienna, Austria).

Institutional Review Board Approval
Institutional review board is not applicable for systematic reviews and meta-analyses.

RESULTS
Study Selection and Characteristics
A total of 2031 citations were identified, of which 46
studies were potentially relevant and retrieved as full
text. Six publications16–21 fulfilled our eligibility criteria
(Figure 1). Characteristics of each study and their patients are shown in Tables 1 through 3. A total of 749
patients (TVI+PVR, 278 patients; PVR, 471 patients)
were included from studies published from 2015 to
2020. All studies were nonrandomized observational
studies. Of all patients, 60.8% were male (450/740),
and 65.8% (487/740) had a transannular patch. TOF
constituted 84.6% (656/775), while 15.2% (118/775) of
patients had pulmonary stenosis. The pooled age at
initial repair was 4.96 years (4 studies, 688 patients),

TVI at PVR: Meta-Analysis

and the pooled age at PVR was 34.3 years (6 studies, 775 patients). Outcomes were reported for a mean
follow-up of 10.2 months (5 studies, 721 patients). The
overall internal validity was considered low risk of bias
(Figure S1).

Synthesis of Results
Echocardiographic Parameters
Results from the meta-analyses of echocardiographic
and magnetic resonance imaging (MRI) parameters are
presented in Table 4; forest plots are given in Figures
S2 through S9. Preoperative values were comparable
between TVI+PVR and PVR for all parameters considered, although patients in the TVI+PVR tended to have
a higher TR grade (MD, 0.64; 95% CI, −0.18 to 1.45;
P=0.090; I²=85%). A decrease from preoperative to
postoperative TR grade was evident in both TVI+PVR
(MD, −1.53; 95% CI, −2.28 to −0.79; P=0.002; I²=94%)
and PVR (MD, −0.99; 95% CI, −1.81 to −0.16; P=0.026;
I²=91%). However, there was evidence for a larger decrease in TR grade in the TVI+PVR group compared
with the PVR group (MD, −0.40; 95% CI, −0.75 to
−0.05, P=0.031; I²=75%). As a result, postoperative
TR grade was comparable between both groups (MD,
0.08; 95% CI, −0.14 to 0.29; P=0.342; I²=0%). A clinically relevant reduction in PR grade was also evident
in both TVI+PVR (MD, −2.53; 95% CI, −3.98 to −1.07;
P=0.029; I²=36%) and PVR (MD, −2.52; 95% CI, −3.03
to −2.02, P=0.010; I²=0%), although no evidence was
found to state that TVI+PVR was associated with a
larger decrease in PR (MD, 0.03; 95% CI, −0.86 to
0.92; P=0.711; I²=75%).
With regard to TV annulus size, a clear decrease
from preoperative to postoperative was observed in
TVI+PVR (MD, −6.43 mm; 95% CI, −10.59 to −2.27;
P=0.032), whereas it was not evident whether a similar
effect was present in the PVR group (MD, −4.20; 95%
CI, −10.42 to 2.02; P=0.074; I²=0%) (Table 4). Although
no evidence was found for an effect of either TVI+PVR
or PVR on qualitative score for RV dilatation, TVI+PVR
tended to be associated with a greater increase in
qualitative score for RV dilatation compared with PVR
(MD, 0.14; 95% CI, 0.08 to 0.19; P=0.020; I²=0%); however, this result should be interpreted cautiously given
that Lueck et al18 reported a tendency toward an increase in RV dilatation, whereas Kogon et al21 reported
a decrease in RV dilatation with both procedures. No
evidence of effects of either treatment or differences
between the effects could be observed with regard to
RV dysfunction as qualitatively assessed by echocardiography (Table 4).
RV end-
diastolic area and RV end-
systolic area
were reported by only one study. Cramer et al20 reported a decrease from preoperative to postoperative
RV end-diastolic area in both TVI+PVR (39.6±12.0 cm²
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Figure 1.

TVI at PVR: Meta-Analysis

Flow diagram of studies included in data search.

to 28.6±5.7 cm²; P=0.001) and PVR (36.2±12.0 cm² to
28.7±8.8 cm²; P=0.040). In contrast, they found no evidence of an effect of RV end-systolic area with either
TVI+PVR (28.4±8.5 cm² to 23.1±13.1 cm², P=0.16) or
PVR (25.1±8.6 cm² to 20.1±7.2 cm², P=0.07).
MRI Parameters
A clinically relevant decrease from preoperative to
postoperative RVEDV was observed in both TVI+PVR
(MD, −84.5 mL; 95% CI, −107 to −61.6; P=0.004) and
PVR (MD, −76.7 mL; 95% CI, −114 to −39.1; P=0.013).

Similarly, a clinically relevant decrease was observed
for RVESV in both TVI+PVR (MD, −28.5 mL; 95% CI,
−37.7 to −19.3; P=0.006) and PVR (MD, −25.8 mL;
95% CI, −39.2 to −12.5; P=0.014). However, no
evidence could be found for any differences between both treatments with regard to the decreases
in RVEDV (MD, −0.74; 95% CI, −24.90 to 23.43;
P=0.908; I²=62%) and RVESV (MD, −0.37; 95% CI,
−11.84 to 11.09; P=0.901; I²=12%). No evidence of
effects of either treatment nor differences between
the effects could be observed with regard to RVEF
(Table 4).
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FU indicates follow-up; M, multicenter; ND, not determined; NM, nonmulticenter; NP, nonprospective; NR, nonrandomized; P, prospective; PVR, pulmonary valve replacement; R, randomized; TR, tricuspid regurgitation;
and TVI, tricuspid valve intervention.

TR grade: 2.7±0.5 in TVI+PVR, 2.2±0.4 in PVR

TR grade: 2.63±0.43 in TVI+PVR, 2.08±0.26 in PVR

6 mo

7.0±2.8 y
35 (16 TVI+PVR, 19 PVR)

36 (18 TVI+PVR, 18 PVR)
NP, NR, NM
USA

USA
2015
Kogon21

2002–2008

2015
Cramer20

1999–2012

NP, NR, NM

Moderate TR in 24 (8 TVI+PVR, 16 PVR), severe TR in 17
(8 TVI+PVR, 9 PVR)
54.6±36.6 mo
France
2017
Roubertie19

2002–2014

NP, NR, NM

41 (16 TVI+PVR, 25 PVR)

TR grade: 2.79±0.95 in TVI+PVR, 1.45±0.56 in PVR

TR grade: 2.0±0.77 in TVI+PVR, 1.94±0.62 in PVR

5.5±2.7 mo

ND

67 (38 TVI+PVR, 29 PVR)

28 (10 TVI+PVR, 18 PVR)
Germany

NP, NR, NM
South Korea

2018

2009–2017

2019

Lueck18

Deshaies

Taejung Kim17

2000–2016

NP, NR, NM

Mild TR in 254 (19 TVI+PVR, 235 PVR), moderate TR
in 192 (90 TVI+PVR, 102 PVR), severe TR in 72 (68
TVI+PVR, 4 PVR)
3 mo
542 (180 TVI+PVR, 362 PVR)
Canada
2020

2000–2016

NP, NR, NM

TR grade
FU time
Design
Country
Study period
Year
First author

16
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Patient no.
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NYHA Class
NYHA class was only reported by a single study.
Roubertie et al19 demonstrated that postoperative
NYHA class was better in TVI+PVR compared with
PVR in patients who had preoperative severe TR (postoperative NYHA class I in 8/8 [100%] with TVI+PVR
versus 2/9 [22.2%] with PVR, respectively; P=0.004),
whereas they could find no evidence for a benefit of
concomitant TVI in patients with preoperative moderate TR (7/8 [87.5%] versus 16/16 [100%], respectively;
P=0.333).
Short-Term Outcomes
The overall OR for 30-day mortality showed no evidence of a difference between TVI+PVR and PVR (OR,
1.86; 95% CI, 0.24 to 14.61; P=0.324) (Figure S10).
Reoperation for TR was only reported by Roubertie et
al19 and they could establish no evidence for a different between both groups. In this study, 2 of 9 (22%) of
patients with severe TR who had undergone isolated
PVR required reoperations, compared with 0 of 8 (0%)
in the TVI+PVR arm (P=0.47).
Sensitivity Analysis
The treatment effect estimates from fixed-effects models were largely comparable to those from random-
effects models (Figures S2–
S10). In contrast to the
random-
effects models, the fixed-
effects models
suggested some evidence for a greater decrease in
TV annulus size (MD, −2.47; 95% CI, −2.91 to −2.03;
P<0.001), a greater increase in RV dysfunction as
qualitatively assessed by echocardiography (MD, 0.29;
95% CI, 0.12 to 0.46; P<0.001), and a smaller increase
in RVEF (MD, −6.41; 95% CI, −7.80 to −5.02; P<0.001)
with TVI+PVR compared with PVR; however, all of these
results should be interpreted with caution given the important statistical heterogeneity in these analyses (I² of
93%, 25%, and 99%, respectively). Furthermore, the
greater increase in qualitative score for RV dilatation
with TVI+PVR compared with PVR was no longer evident in fixed-effects analyses (OR, 0.14; 95% CI, −0.01
to 0.29; P=0.077); no evidence for heterogeneity was
evident in this analysis (I²=0%).

DISCUSSION
Summary of Evidence
This meta-analysis investigated the effect of concomitant TVI at the time of PVR in ACHD. The key findings
are summarized in Figure 2. Our results demonstrated
that both TVI+PVR and PVR reduced TR grade, PR
grade, RVEDV, and RVESV. TVI+PVR, but not PVR
alone, was associated with a decrease in TV annulus
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9 (pulmonary arterioplasty in 2, VSD closure in 2,
Maze procedure in 2, CABG in 1)

Comments

CABG indicates coronary artery bypass grafting; ND, not determined; TVI, tricuspid valve intervention; and VSD, ventricular septal defect.

12 (Maze procedure)
0

size after the procedure. Furthermore, TVI+PVR was
associated with a larger decrease in TR grade compared with PVR. No evidence could be established
for an effect of either treatment on RVEF or echocardiographic assessment of RV dilatation and dysfunction. There was no evidence for a difference in hospital
mortality or reoperation for TR. These results suggest
that TVI might have a favorable effect on TR grade, although specific indications for combined valve surgery
remain unclear.

1
6

5
57

28
0

3
0

0
3

11
4

13
Kogon 201521

Cramer 2015

20

ND

28
0

0
0

104

28
0

0
7

0

0
Roubertie 201719

16

0
Lueck 201818

10

ND
ND
ND
ND
4 leaflet extension, 1 cleft
repair, 2 valve replacement
26
26
Taejung Kim 201917

11

328 (branch pulmonary arterioplasty in 109,
residual VSD closure in 38, atrial ablation in 68,
ventricular ablation in 70, CABG in 18, mitral
valve procedure in 8, aortic valve procedure in 7,
thoracic aorta±aortic valve in 5, other in 5)
ND
ND
ND
15 replacements
(1 mechanical valve, 14
bioprostheses)
38
34
Deshaies 202016

93

Bioprosthetic
valved conduit
Bioprosthetic
valve
Other/combination
Commissuroplasty
Suture

Ring

TVI at PVR: Meta-Analysis

Author

Tricuspid valve annuloplasty type

Table 2. Procedure Characteristics
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Pulmonary valve replacement type

Mechanical
valve

Concomitant procedures other than TVI

Van den Eynde et al

Dilatation of the RV is a common complication following repair of TOF, pulmonary stenosis, and pulmonary
atresia, primarily attributable to chronic PR.1 This,
in turn, leads to dilatation of the TV annulus, resulting in varying degrees of TR and further RV dilatation. Although the transannular patch repair approach
causes PR, many additional factors can contribute to
TR in these patients.22 These include damage to the TV
leaflets or chordae tendineae during initial surgery, as
well as the presence of additional valve abnormalities.
Regardless of the causative mechanism, moderate to
severe preoperative TR is a well-described risk factor
for adverse outcomes in ACHD, leading to heart failure,
arrhythmia, and death.6 Although concomitant TVI has
been shown to reduce TR in these patients, there has
been considerable debate regarding this approach.
Several studies have recommended PVR alone to
address both PR and TR following TOF repair, arguing that the reduction in RV volume overload resulting
from PVR is enough to ameliorate the observed TR. In
a comparison between patients undergoing PVR alone
versus those with TVI+PVR, Kogon et al21 found that
patients in the latter group experienced a greater increase in TR at medium follow-up (7.0±2.8 years). These
results led them to recommend PVR alone in patients
with moderate or greater TR. Similarly, Kurkluoglu et
al23 found that dilatation of the TV annulus improved
after PVR alone, suggesting that additional parameters
should be taken into account when evaluating patients
for TVI+PVR. Results from a single-center study by
Lueck et al18 found longer intensive care unit stays for
the TVI+PVR group, as well as greater rates of arrhythmia, renal insufficiency, sternal wound infection, and
delirium. Notably, all of these findings were drawn from
single-center studies composed of relatively small populations. Conversely, results from a multicenter study
performed by Deshaies et al16 found that TVI+PVR results in a greater reduction in TR. With the exception
of a slightly higher incidence of major infections, there
was no evidence for differences in adverse outcomes
between TVI+PVR and PVR alone.
Another area of debate that our study could not
address is the optimal treatment strategy for patients
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16

19

TVI+PVR

PVR

ND

ND

ND

36

ND

ND

ND

ND

64

ND

ND

17

24

16

40

204

89

293

Male sex

ND

ND

ND

50

ND

ND

ND

ND

62

ND

ND

21

22

18

40

225

89

314

Trans-annular
patch

6.1±9.9

10.7±13

7.8±11.1

6.9±3.6

1.7±0.75

2.3±3.4

1.4±1.7

1.7±0.6

1.7±1.4

ND

ND

ND

ND

ND

ND

4.2±0.78

6.4±1.4

4.8±0.91

Age at
initial
repair, y

32.3±14.6

31.9±16.3

31.3±16.7

35.2±8.5

27.8±10.0

25.6±8.0

26.1±9.0

24.6±12.0

26.3±9.50

ND

ND

41.1±12.5

31.2±15.2

21.7±12.3

ND

34.0±3.2

39.8±4.1

35.6±3.4

Age at PVR, y

26.7±10.6

18.1±11.5

23.5±11.5

29.5±6.2

26.2±9.0

24.8±8.0

24.9±9.0

23.0±12.0

24.8±9.3

ND

ND

32.0±9.5

ND

ND

ND

ND

ND

ND

Interval time, y

15

11

26

62

9

16

8

8

96

18

10

28

38

28

66

304

129

433

TOF

4

5

9

0

0

0

0

0

2

0

0

0

0

0

0

58

51

109

PS

0

0

0

0

0

0

0

0

1

0

0

0

0

0

0

0

0

0

PA

Original congenital
diagnosis

0

0

0

0

0

0

0

0

5
DORV
with
VSD
and
PS

0

0

0

0

0

0

0

0

0

Other

ND

ND

ND

ND

ND

ND

ND

ND

94.3±48.1

153

164

ND

ND

ND

ND

88.5±8.6

128.5±9.6

102.0±11.0

Cardiopulmonary
bypass time, min

ND

ND

ND

ND

ND

ND

ND

ND

68.1±23.0

63.5

71.0

ND

ND

ND

ND

69.8±7.5

53.8±5.5

60.0±6.7

Aortic cross-
clamp time, min

Operative characteristics

DORV indicates double outlet right ventricle; ND, not determined; PA, pulmonary atresia; PS, pulmonary stenosis; PVR, pulmonary valve replacement; TR, tricuspid regurgitation; TVI, tricuspid valve intervention; and
VSD, ventricular septal defect.

35

62

9

PVR
(severe
TR)

All patients

16

PVR
(moderate
TR)

All patients

8

TVI+PVR
(severe
TR)

Kogon 201521

8

TVI+PVR
(moderate
TR)

18

PVR

104

10

TVI+PVR

All patients

28

All patients

38

TVI+PVR

Cramer 201520

Roubertie 201719

Lueck 2018

18

29

PVR

362

67

PVR

All patients

180

TVI+PVR

Taejung Kim 201917

542

All patients

Deshaies 202016

Patient no.

Group

Author

Baseline characteristics

Table 3. Baseline and Operative Characteristics of Patients Included in the Study
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RVEDV (mL)

RV dysfunction (0–3)

RV dilatation (0–3)

TV annulus (mm)

3 (34 TVI+PVR/43 PVR)
3 (34 TVI+PVR)
3 (43 PVR)
3 (34 TVI+PVR/43 PVR)

Change from preoperative to postoperative in TVI+PVR

Change from preoperative to postoperative in PVR

Difference in change with TVI+PVR vs PVR*

2 (26 TVI+PVR/37 PVR)

Difference in change with TVI+PVR vs PVR*

Postoperative TVI+PVR vs PVR

2 (37 PVR)

Change from preoperative to postoperative in PVR

3 (34 TVI+PVR/43 PVR)

2 (26 TVI+PVR)

Change from preoperative to postoperative in TVI+PVR

Preoperative TVI+PVR vs PVR

2 (26 TVI+PVR/37 PVR)

2 (26 TVI+PVR//37 PVR)

Difference in change with TVI+PVR vs PVR*

Postoperative TVI+PVR vs PVR

2 (37 PVR)

Change from preoperative to postoperative in PVR

2 (26 TVI+PVR/37 PVR)

2 (26 TVI+PVR)

Change from preoperative to postoperative in TVI+PVR

Preoperative TVI+PVR vs PVR

2 (26 TVI+PVR/37 PVR)

2 (56 TVI+PVR/47 PVR)

Difference in change with TVI+PVR vs PVR*
2 (26 TVI+PVR/37 PVR)

2 (47 PVR)

Change from preoperative to postoperative in PVR

Postoperative TVI+PVR vs PVR

2 (56 TVI+PVR)

Preoperative TVI+PVR vs PVR

2 (56 TVI+PVR/47 PVR)

Change from preoperative to postoperative in TVI+PVR

2 (34 TVI+PVR/37 PVR)

Difference in change with TVI+PVR vs PVR*

Postoperative TVI+PVR vs PVR

2 (37 PVR)

Change from preoperative to postoperative in PVR

2 (56 TVI+PVR/47 PVR)

2 (34 TVI+PVR)

Change from preoperative to postoperative in TVI+PVR

Preoperative TVI+PVR vs PVR

2 (34 TVI+PVR/37 PVR)

7 (249 TVI+PVR/415 PVR)

Difference in change with TVI+PVR vs PVR*

Postoperative TVI+PVR vs PVR

7 (415 PVR)

Change from preoperative to postoperative in PVR

2 (34 TVI+PVR/37 PVR)

7 (249 TVI+PVR)

Change from preoperative to postoperative in TVI+PVR

Preoperative TVI+PVR vs PVR

4 (82 TVI+PVR/84 PVR)

Postoperative TVI+PVR vs PVR

PR grade (0–3)

4 (82 TVI+PVR/84 PVR)

Preoperative TVI+PVR vs PVR

TR grade (0–3)

No. of (sub)studies (No. of
patients)

Comparison

Variable (unit)

Summary of Outcomes
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Table 4.

−0.74 mL (−24.90 to 23.43)

−76.66 mL (−114.22 to −39.11)

−84.46 mL (−107.36 to −61.57)

−2.87 mL (−23.83 to 18.09)

1.07 mL (−32.04 to 34.18)

0.28 (−1.05 to 1.62)

0.04 (−5.61 to 5.69)

0.25 (−3.94 to 4.43)

0.71 (−2.21 to 3.63)

0.39 (−1.32 to 2.10)

0.14 (0.08 to 0.19)

−0.24 (−6.52 to 6.04)

−0.14 (−6.32 to 6.04)

0.22 (−0.73 to 1.18)

0.08 (−0.90 to 1.06)

−2.45 mm (−13.25 to 8.35)

−4.20 mm (−10.42 to 2.02)

−6.43 mm (−10.59 to −2.27)

−1.50 mm (−21.18 to 18.19)

1.10 mm (−7.44 to 9.09)

0.03 (−0.85;0.0.92)

−2.52 (−3.03 to −2.02)

−2.53 (−3.98 to −1.07)

−0.01 (−0.25 to 0.23)

−0.03 (−0.59 to 0.53)

−0.40 (−0.75 to −0.05)

−0.99 (−1.81 to −0.16)

−1.53 (−2.28 to −0.79)

0.08 (−0.14 to 0.29)

0.64 (−0.18 to 1.45)

MD (95% CI)

0.908

0.013

0.004

0.615

0.902

0.277

0.948

0.592

0.199

0.212

0.020

0.714

0.823

0.207

0.490

0.212

0.074

0.032

0.511

0.350

0.711

0.010

0.029

0.603

0.657

0.031

0.026

0.002

0.342

0.090

P value

62

25

0

0

0

25

76

33

0

0

0

85

71

0

0

93

0

0

82

0

75

0

36

0

30

75

91

94

0

85

I² (%)

0.072

0.264

0.405

0.502

0.416

0.247

0.040

0.222

0.334

0.574

0.956

0.011

0.065

0.732

0.713

(Continued)

<0.001

0.592

0.550

0.020

0.425

0.045

0.701

0.210

0.889

0.234

<0.001

<0.001

<0.001

0.670

<0.001

P value
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3 (34 TVI+PVR/43 PVR)
Difference in change with TVI+PVR vs PVR*

MD indicates mean difference; PR, pulmonary regurgitation; PVR, pulmonary valve regurgitation; RV, right ventricular; RVEDV, right ventricular end-diastolic volume; RVEF, right ventricular ejection fraction; RVESV,
right ventricular end-systolic volume; TR, tricuspid regurgitation; TV, tricuspid valve; and TVI, tricuspid valve intervention.
*(Difference in change with TVI+PVR vs PVR)=(Change from preoperative to postoperative in TVI+PVR)−(Change from preoperative to postoperative in PVR).

<0.001

<0.001
97

99
0.460

0.310
3 (43 PVR)
Change from preoperative to postoperative in PVR

−6.00% (−34.44 to 22.45)

3 (34 TVI+PVR)

14.35% (−31.49 to 60.19)

<0.001

0.008
79
0.185

<0.001

Change from preoperative to postoperative in TVI+PVR

8.38% (−9.77 to 26.54)

90
0.368
6.96% (−18.98 to 32.89)
3 (34 TVI+PVR/43 PVR)
Postoperative TVI+PVR vs PVR

0.320
12

97
0.420

0.901
−0.37 mL (−11.84 to 11.09)

12.77% (−41.75 to 67.30)
3 (34 TVI+PVR/43 PVR)

3 (34 TVI+PVR/43 PVR)
Difference in change with TVI+PVR vs PVR*

Preoperative TVI+PVR vs PVR

3 (43 PVR)
Change from preoperative to postoperative in PVR

RVEF (%)

0.863

0.704
0
0.014

0.934

Change from preoperative to postoperative in TVI+PVR

−25.83 mL (−39.20 to −12.46)

0
0.006
3 (34 TVI+PVR)

Postoperative TVI+PVR vs PVR

−28.45 mL (−37.65 to −19.25)

0.388
0

0
0.934

0.855

3 (34 TVI+PVR/43 PVR)

Preoperative TVI+PVR vs PVR
RVESV (mL)

−0.39 mL (−18.28 to 17.51)

3 (34 TVI+PVR/43 PVR)

Comparison

1.32 mL (−26.18 to 28.82)
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Variable (unit)

Table 4.

Continued
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No. of (sub)studies (No. of
patients)

MD (95% CI)

P value

I² (%)

P value
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who undergo TVI. With the exception of Lueck et al,18
where the TV was replaced in all 10 of their patients
with TVI+PVR, TV repair was the most common TVI in
the studies we analyzed. This is similar to other studies of ACHD patients undergoing TVI. A recent single-
center study from Australia analyzing TVI in adults with
Ebstein anomaly and other ACHD found that TV repair
was performed in 61% (22/36) of their cohort, while the
remaining 39% (14/36) underwent TV replacement.24
In this cohort, 4 patients required reintervention (with
1 death 9 days after reintervention), of which 2 had initial TV replacement and 2 underwent TV repair. Of the
30 patients with available echocardiographic data, all
5 with moderate or greater TR underwent TV repair.24
In an analysis of 109 TV repairs and 19 replacements
in 128 patients with ACHD other than Ebstein anomaly, Lo Rito et al25 found that those who underwent
suture annuloplasty had a higher rate of moderate or
greater TR at latest follow-up (4.95 years; 7.7 interquartile range) compared with those with ring annuloplasty.
The only patient who required TV reintervention had an
initial biological valve replacement. Importantly, both
studies describe a high incidence of atrial arrhythmias
following TVI, regardless of surgical approach.25,26
Currently, there are not enough data to identify which
patients may benefit the most from concomitant TVI.
Our study, however, highlights several salient features
that warrant further exploration. In the only included
study to report NYHA class, Roubertie et al19 found
that patients with severe preoperative TR experienced
an improvement in NYHA class and TR grade following
TVI+PVR. This study similarly found no patients with
residual moderate or greater TR in the TVI+PVR group,
compared with 78% (7/9) of those with PVR alone
when analyzing patients with severe TR before surgery.
In accordance with this, Deshaies et al16 found that
severe preoperative TR was associated with a higher
risk of residual postoperative TR (OR, 9.43; 95% CI,
4.20–21.33; P<0.001), while TVI+PVR reduced this risk
(OR, 0.44; 95% CI, 0.25–0.77; P=0.004). Importantly,
only 5.6% (4/72) of patients with severe preoperative
TR underwent isolated PVR in this study. In the Cramer
et al20 series, 75% (12/16) of patients with severe TR
had TVI+PVR, with both approaches resulting in mild
residual TR at 6-month follow-up.
Although TR grade and measurements of cardiac
volumes and function are valuable indices of the efficacy of TVI, the actual goal of such intervention in
ACHD should be the prevention of adverse events
such as arrhythmias and heart failure. In this regard,
the results of a study by Bokma et al6 are concerning.
In their cohort of 129 patients with TOF undergoing
isolated PVR, those with severe preoperative TR remained at increased risk for adverse events (including death, sustained ventricular tachycardia, heart
failure, or supraventricular tachycardia), regardless of
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Figure 2. Summary of the key findings of the meta-analysis.
Both TVI+PVR and PVR reduced TR grade, PR grade, RVEDV, and RVESV. TVI+PVR, but not PVR, was
associated with a decrease in TV annulus. Furthermore, TVI+PVR was associated with a larger decrease in
TR grade compared with PVR. No evidence could be established for an effect of either treatment on RVEF
or RV dilatation and RV dysfunction as qualitatively assessed by echocardiography of either treatment.
There was no evidence for a difference in hospital mortality or reoperation for TR. PR indicates pulmonary
regurgitation; PVR, pulmonary valve replacement; RV, right ventricular; RVEDV, right ventricular end-
diastolic volume; RVEF, right ventricular ejection fraction; RVESV, right ventricular end-systolic volume;
TR, tricuspid regurgitation; TV, tricuspid valve; and TVI, tricuspid valve intervention.

their postoperative TR grade. The authors suggested
that both long-standing volume overload attributable
to PR and long-standing right atrial volume and pressure overload attributable to TR might contribute to
this risk, leading to RV dysfunction and arrhythmias,
respectively. While our findings suggest that patients with severe preoperative TR benefit most from
TVI+PVR in terms of improvement of TR grade, a benefit in terms of “hard” outcomes can thus not be directly inferred. These data therefore do not support the
universal application of this approach for severe TR.
Further well-designed studies focusing on specific underlying mechanisms of TR and evaluating the effect
on adverse events on long-term follow-up may elucidate which patients stand to benefit the most from this
approach.

Sources of Heterogeneity
Given the nonrandomized nature of the existing studies comparing TVI+PVR against PVR, underlying
center-and surgeon-specific bias with regard to treatment allocation was likely. Kogon et al21 intervened
on 46% (16/35) of patients with moderate or greater
TR, stating bias toward a conservative approach

based on their prior work 26 showing improvement in
TV function without concomitant TVI, a view shared
by Cramer et al.20 In contrast, Taejung Kim et al17
performed concomitant TVI in 56.7% (38/67) of patients in their cohort, with no signficant difference in
baseline TV annulus diameter but larger RV volumes
in their TVI+PVR group, reflecting a more aggressive
approach to TR at their center. In Deshaies et al,16
almost 59.8% (158/264) of patients with moderate or
greater TR had TVI+PVR, as opposed to only 7.9%
(22/278) of those with mild TR. Taken together, these
data suggest that considerable heterogeneity may
have been present with regard to indications for concomitant TVI. Such indication bias would be expected
to result in a greater prevalence of higher-risk patients
in the TVI+PVR group, as observed in the studies by
Taejung Kim et al,17 Cramer et al,20 and Kogon et al.21
In every study reviewed for this meta-analysis, the
addition of TVI was performed on the basis of surgeon and cardiologist preference, which further adds
patient-specific heterogeneity regardless of the degree of preoperative TR.
The use of echocardiography and/or MRI also varied among studies. While the use of cardiac MRI has
evolved in recent years, only Roubertie et al19 and
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Taejung Kim et al17 incorporated MRI data into their
analyses out of the 6 included studies. Expanded use
of cardiac MRI can further quantify TV function and
help better understand the role of concomitant TVI in
patients with TOF and PR.

Limitations
While the use of meta-analysis enabled us to pool studies and increase our sample size, we were ultimately
limited to 6 studies that met the inclusion criteria of
comparing PVR with and without concomitant TVI.
Accordingly, some of the analyses were based on a low
number of subjects. As described earlier, our results
may have been susceptible to selection bias. Another
limitation is the lack of data regarding patient anatomy
and underlying causes of TR, which can be critical in
determining when TVI+PVR offers the greatest benefit.
Since all included studies focused on adults with childhood TOF repair, the operative technique and age at
repair reflect treatment strategies from earlier decades,
which have since evolved.27,28 Furthermore, long-term
follow-
up studies of patients with TVI+PVR remains
scarce, which precludes the ability to draw definitive
conclusions on durability of the results.
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Data S1.
Supplemental Methods
Search strategy.
PubMed (n=393 on 29/12/2020)
("Pulmonary Valve"[Mesh] OR “Pulmonary valve*” OR “Valves, Pulmonary” OR “Valve,
Pulmonary”) AND (“Replacement*” OR “Replantation*” OR “Surgical Replantation*” OR
“Replantation, Surgical” OR “Reimplantation*”) AND ("Tricuspid Valve"[Mesh] OR
“Tricuspid valve*” OR “Valve, Tricuspid” OR “Valves, Tricuspid” OR “Tricuspid”)

Embase (n=709 on 29/12/2020)

(('pulmonary valve'/exp AND ('replacement' OR 'replantation' OR 'reimplantation')) OR
'pulmonary valve replacement'/exp OR 'pulmonary valve replacement') AND ('tricuspid
valve'/exp OR 'tricuspid valve' OR 'tricuspid')

Scopus (n=929 on 29/12/2020)
Downloaded from http://ahajournals.org by on February 2, 2022

( TITLE-ABS-KEY ( "Pulmonary valve*" OR "Valves, Pulmonary" OR "Valve, Pulmonary"
)

AND

TITLE-ABS-KEY ( "Replacement*"

OR

"Replantation*"

OR

"Surgical

Replantation*" OR "Replantation,Surgical" OR "Reimplantation*" ) AND TITLE-ABSKEY ( "Tricuspid valve*" OR "Valve, Tricuspid" OR "Valves, Tricuspid" OR "Tricuspid"
))

Figure S1. Bias assessment of observational studies (ROBINS-1 tool).
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Figure S2. Forest plots for TR grade (0-3). Pooled mean difference and conclusions plot
for all comparisons. CI, confidence interval; MD, mean difference; PVR, pulmonary valve
replacement; SD, standard deviation; TR, tricuspid regurgitation; TVI, tricuspid valve
intervention.
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Figure S3. Forest plots for PR grade (0-3). Pooled mean difference and conclusions plot
for all comparisons. CI, confidence interval; MD, mean difference; PR, pulmonary
regurgitation; PVR, pulmonary valve replacement; SD, standard deviation; TVI, tricuspid valve
intervention.
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Figure S4. Forest plots for TV annulus (mm). Pooled mean difference and conclusions plot
for all comparisons. CI, confidence interval; MD, mean difference; PVR, pulmonary valve
replacement; SD, standard deviation; TV, tricuspid valve; TVI, tricuspid valve intervention.
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Figure S5. Forest plots for RV dilatation (0-3). Pooled mean difference and conclusions
plot for all comparisons. CI, confidence interval; MD, mean difference; PVR, pulmonary
valve replacement; RV, right ventricular; SD, standard deviation; TVI, tricuspid valve
intervention.
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Figure S6. Forest plots for RV dysfunction (0-3). Pooled mean difference and conclusions
plot for all comparisons. CI, confidence interval; MD, mean difference; PVR, pulmonary
valve replacement; RV, right ventricular; SD, standard deviation; TVI, tricuspid valve
intervention.
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Figure S7. Forest plots for RVEDV (mL). Pooled mean difference and conclusions plot
for all comparisons. CI, confidence interval; MD, mean difference; PVR, pulmonary valve
replacement; RVEDV, right ventricular end-diastolic volume; SD, standard deviation; TVI,
tricuspid valve intervention.
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Figure S8. Forest plots for RVESV (mL). Pooled mean difference and conclusions plot for
all comparisons. CI, confidence interval; MD, mean difference; PVR, pulmonary valve
replacement; RVESV, right ventricular end-systolic volume; SD, standard deviation; TVI,
tricuspid valve intervention.
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Figure S9. Forest plots for RVEF (%). Pooled mean difference and conclusions plot for
all comparisons. CI, confidence interval; MD, mean difference; PVR, pulmonary valve
replacement; RVEF, right ventricular ejection fraction; SD, standard deviation; TVI, tricuspid
valve intervention.
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Figure S10. Forest plot for 30-day mortality. Pooled odds ratio and conclusions plot. CI,
confidence interval; OR, odds ratio; PVR, pulmonary valve replacement; TVI, tricuspid valve
intervention.
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